CD5 CAR T Cells for T-ALL Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell therapies, such as CAR T cells, face challenges in targeting T-cell malignancies due to shared expression of antigens between normal and malignant T cells, leading to fratricide and limited efficacy for T-lineage Acute Lymphoblastic Leukemia (T-ALL) and other T-cell leukemias.
Innovation Solution
Development of a CD5-specific chimeric antigen receptor (CAR) that targets CD5-positive cells, including T-ALL and T-cell lymphomas, with engineered immune cells expressing a CD5 CAR to selectively eliminate malignant cells while minimizing toxicity to normal T cells, utilizing a CD5 CAR comprising an anti-CD5 scFv, IgG Fc spacer, and intracellular signaling domains from CD28 and TCR zeta chain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cells are used to target T-cell malignancies, then cancer cell elimination is achieved, but normal T cells are harmed due to shared antigen expression
Solution Approach 1:
The patent segments the CAR structure into distinct functional domains: a CD5-specific antigen-binding domain (scFv), a transmembrane domain, and intracellular signaling domains (CD3ζ, CD28, 4-1BB). This segmentation allows the CAR to selectively recognize CD5 on cancer cells while the signaling domains provide controlled cytotoxic response, thereby improving cancer elimination efficacy while reducing off-target toxicity to normal T cells.
Solution Approach 2:
The patent applies local quality by using a CD5-specific scFv domain that is exclusively expressed on the CAR T cells, creating a localized recognition capability for CD5-positive cancer cells. This specificity ensures that the harmful cytotoxic effect is confined to CD5-expressing malignant cells rather than affecting all T cells, thus resolving the contradiction between cancer elimination and normal cell preservation.
2Object-affected harmful factors
If CD5 CAR is designed with high specificity for CD5 antigen, then fratricide is minimized, but cancer cell recognition capability must be enhanced
Solution Approach 1:
The patent merges multiple functional elements into a single CAR construct: the CD5-specific scFv for recognition, CD3ζ for primary signaling, CD28 for costimulation, and 4-1BB for enhanced activation. This combination creates a synergistic effect where the CAR T cells exhibit both high specificity for CD5 (minimizing fratricide) and enhanced cancer cell recognition/cytotoxicity through the combined signaling pathways.
Solution Approach 2:
The CAR is designed as a composite receptor structure integrating different functional domains with complementary properties. The scFv provides specific binding, while the intracellular domains (CD3ζ, CD28, 4-1BB) provide layered signaling that enhances cancer cell recognition and killing. This composite design allows simultaneous achievement of high specificity and strong antitumor activity without increasing fratricide.
3Reliability
If CAR T cells are engineered with multiple signaling domains, then antitumor activity is enhanced, but device complexity increases
Solution Approach 1:
The patent implements multi-functionality by incorporating multiple signaling domains (CD3ζ, CD28, 4-1BB) into a single CAR construct that can be expressed on T cells. This universal CAR design performs multiple functions: CD3ζ provides primary activation, CD28 adds costimulation, and 4-1BB enhances activation and persistence. The multi-functional CAR achieves enhanced antitumor activity while maintaining a single, manageable molecular structure rather than requiring multiple separate receptors.
Data Source
AI summary
Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.